Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

N/ANo Longer AvailableNCT03066661

Hoffmann-La Roche

Overview

Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for entrectinib.

Study Type

EXPANDED_ACCESS

Conditions

Cancers With NTRK, ROS1, or ALK Gene Fusions

Interventions

EntrectinibDRUG

Open-label expanded access, capsules

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of advanced cancer with an NTRK1, NTRK2, NTRK3, ROS1, or ALK gene fusion * Unable to participate in an ongoing entrectinib (RXDX-101) clinical trial * Willing and able to provide written, signed informed consent * Medically suitable for treatment with entrectinib (RXDX-101) Exclusion Criteria: * Currently enrolled in an ongoing clinical study with any other investigational agent

Locations (1)

1-844-Startrk (782-7875)

San Diego, California, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.